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Abstract 
 
Introduction: Systemic light-chain (AL) amyloidosis is an infiltrative disorder associated with an 
underlying plasma cells dyscrasia, in which monoclonal immunoglobulin light chains accumulate in 
an abnormal misfolded form as amyloid fibrils in the extracellular space. Symptoms and prognosis 
are governed by which organs are affected, and cardiac involvement is the major determinant of 
survival. Diagnosis requires demonstration of amyloid deposition and confirmation of the fibril 
protein type.  
Areas Covered: This review will focus on the available treatments for systemic AL amyloidosis and 
on new drug targets and therapeutic approaches.  
Expert opinion: At present, the choice of upfront treatment lies between autologous stem cell 
transplantation (ASCT) and combination chemotherapy. Chemotherapy agents include 
dexamethasone, melphalan, cyclophosphamide, thalidomide, bortezomib, lenalidomide, 
bendamustine in various combinations.   Few randomized controlled trials have been performed in 
AL amyloidosis and treatment has been substantially influenced by clinical practice in myeloma.  It 
has become clear that the best prospects of survival and preservation or improvement in amyloid 
related organ function require as near complete suppression as possible of the underlying 
hematological disorder. Future directions include therapies designed to target amyloid deposits 
directly, in particular anti-amyloid antibodies which are now well advanced in development and 
are showing great potential. 
Keywords: immunoglobulin light-chain amyloidosis, screening, treatments, combination 
chemotherapy, stem cell transplantation, immunotherapeutic targeting, new frontiers. 
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 Systemic light-chain (AL) amyloidosis is an infiltrative 
disorder associated with an underlying plasma cells dyscrasia, 
in which monoclonal immunoglobulin light chains accumulate 
in an abnormal misfolded form as amyloid fibrils in the 
extracellular space and disrupt organ function.  
 The presenting clinical picture of patients with systemic AL 
amyloidosis is variable and non-specific. This is associated 
with a significant delay in the diagnosis, with 30% of patients 
presenting with a prognosis of less than 12 months. Screening 
of pre-symptomatic organ damage has the potential to change 
this. 
 The use of autologous stem cell transplantation (ACST) with 
high dose melphalan is associated with excellent and durable 
clonal responses, but only 20-25% of patients are currently 
eligible (low risk patients). Accurate patient selection, based 
on blood biomarkers, is crucial to reduce treatment related 
mortality. The intermediate and high risk patients should be 
considered for combination chemotherapy (melphalan-
dexamethasone , bortezomib - cyclophosphamide - 
dexamethasone, bortezomib - melphalan -dexamethasone). 
Patients with relapsed or refractory disease should be 
considered for treatment with agents including 
bendamustine, lenalidomide and pomalidomide. 
 Patients achieving a hematologic complete response/very 
good partial response have the best chance to achieve organ 
responses, but stabilization or improvement in amyloidotic 
organ function occur also in a proportion of patients who 
achieved only partial hematologic responses. Tracking organ 
function very closely  during chemotherapy  is essential. 
Review after 3 cycles of treatment is suggested with dose 
increments, additional agents or alternative regimens in 
patients responding poorly. 
 New treatment strategies, directly targeting amyloid deposits 
and interfering with fibril formation, are currently well 
advanced in development and have the potential to reshape 
the treatment of AL amyloidosis.   
.  
1. Introduction 
Systemic amyloidosis is a rare disease caused by deposition of certain proteins that can misfold 
and aggregate in a highly characteristic fibrillar form within the extracellular space. All amyloid 
fibrils share an insoluble β-pleated sheet structure, and the various clinical amyloidosis disorders 
are classified according to the specific fibril precursor protein. Amyloid deposits can accumulate in 
in many different organs and tissues, progressively disrupting their structure and function [1]. The 
most commonly involved organs are heart, kidneys, gastrointestinal tract, liver and peripheral and 
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autonomic nervous systems. The pattern of organ involvement is highly variable and determines 
the presenting clinical picture.  
Immunoglobulin light chain (AL) amyloidosis is the most common type. This form is associated 
with a clonal plasma cell or, less frequently, B-lymphoid disorder, and AL amyloid fibrils are 
derived from monoclonal kappa or lambda light chains. AL amyloidosis rarely can occur in a 
localised form, typically confined to a single type of tissue, for example the skin, larynx, airways 
and urinary tract. Localised AL amyloidosis can usually be managed with local resection and has an 
excellent prognosis in most patients[2].  
The second most common type is transthyretin amyloidosis (ATTR amyloidosis) in which the 
amyloid fibril protein is derived from transthyretin (TTR), an abundant plasma protein produced by 
the liver. ATTR amyloidosis encompasses wild type ATTR amyloidosis, previously known as senile 
systemic amyloidosis, in which wild type TTR is deposited as amyloid, and hereditary forms, in 
which genetically variant forms of TTR are implicated. Other types of hereditary amyloidosis are 
associated with to certain mutations in the genes for fibrinogen A α-chain, apolipoproteins A1 and 
A2, lysozyme and gelsolin. In AA amyloidosis the fibril protein precursor is the acute phase 
reactant serum amyloid A protein; this type of amyloidosis is a rare complication of many chronic 
inflammatory disorders. The various subtypes of amyloidosis are listed in Table 1. 
This review is focused on current strategies for the treatment of AL amyloidosis. 
 
2. Clinical presentation and diagnosis 
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The presenting clinical picture in systemic AL amyloidosis is extremely variable and dependent on 
the pattern of organ involvement. Symptoms are mostly non-specific including fatigue, dyspnoea, 
weight loss, edema, bleeding tendency, orthostatic hypotension and other features of autonomic 
or peripheral neuropathy. More specific features such as macroglossia and peri-orbital bruising are 
present in a third of cases [3]. The lack of specific clinical features frequently leads to delay in the 
diagnosis, and 30% of patients present with irreversible organ damage and a prognosis of less than 
12 months[4] [5]. Use of biomarkers to detect pre-symptomatic organ damage has the potential to 
change this: serum N-terminal pro b-type natriuretic peptide (NT-proBNP) concentration has high 
diagnostic accuracy for the detection of cardiac involvement in AL amyloidosis [4]and albuminuria 
is an important marker for the detection of kidney infiltration. Biomarker screening therefore has 
a role in patients being followed up with monoclonal gammopathy of uncertain significance, about 
2% of whom are thought to eventually develop systemic amyloidosis [4] (Figure 1).  
Suspicion of AL amyloidosis requires confirmation through demonstration of amyloid in 
histological tissue sections of a biopsy taken from an affected organ or, less invasively, through 
abdominal fat or bone marrow aspiration. Amyloid deposits in tissue sections stain pink with 
Congo red dye and produce diagnostic apple-green birefringence when viewed under cross-
polarized light (Figure 2)[6]. Fibril typing is then critical to determine appropriate therapy and is 
most widely performed through immunohistochemistry, which produces definitive results in about 
two-thirds of patients of AL amyloidosis [7].   Additional approaches include immuno-electron 
microscopy[8] and mass spectrometry, which can identify the amyloid protein in up to 98% of 
cases [9]. Detailed characterization of the underlying clonal hematological disorder is a further 
crucial step in planning the optimal treatment strategy. This includes serum and urine 
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electrophoresis and immunofixation, serum free light chain measurement, bone marrow biopsy 
and imaging for presence of myeloma related bone disease.  
Baseline assessment of amyloid related organ dysfunction informs prognosis and selection of the 
most appropriate treatment. Echocardiography has long been used to assess cardiac involvement, 
but findings can be non-specific and other frequent co-morbidities such as hypertension can result 
obscure interpretation. Cardiac magnetic resonance imaging (CMR) is the most sensitive and 
specific imaging modality for the diagnosis of cardiac amyloidosis[10, 11]. CMR, after the 
administration of contrast, shows a characteristic pattern of global subendocardial late gadolinium 
enhancement (LGE) coupled with abnormal myocardial and blood-pool gadolinium kinetics [11] 
(Figure 3). Bone scintigraphy tracers, 99mTc-dicarboxypropane diphosphonate (99mTc-DPD) and 
99mTc-pyrophosphate (99mTc-PYP), localize with remarkable but unexplained sensitivity in cardiac 
ATTR amyloidosis. Visual scoring of cardiac uptake with 99mTc-DPD scintigraphy according with 
Perugini et al. scale is routinely used in patients with ATTR amyloidosis [12, 13] and the 
combination of high degree of cardiac uptake (grade 2 or 3) in absence of  serum or urine 
monoclonal proteins has been showed to be 100% specific for diagnosing of cardiac ATTR 
amyloidosis [14]. Cardiac localization of this radiotracer also occurs in a small portion of patients 
with AL amyloidosis, and hence endomyocardial biopsy may remain required in patients with 
positive cardiac scintigraphy who have a monoclonal gammopathy, since both AL and ATTR 
amyloidosis are differential diagnoses [15].  
Formal evaluation of peripheral neuropathy and autonomic dysfunction may be useful in patients 
with a predominantly neuropathic phenotype. Serial quantification and monitoring of visceral 
amyloid deposits can be performed with 123I labeled serum amyloid P component (SAP) 
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scintigraphy [16]. This test allows the visualization and quantification of amyloid deposits within 
the liver, spleen, kidneys adrenals and bones, giving a baseline picture of the pattern of organ 
involvement as well as the ability to track changes over time in the specialized centres where the 
technique is available.  
 
 
 
3. Prognosis and staging 
 
Serum troponin-T (TnT) and NT-proBNP measurements are currently the reference standard to 
stratify the prognosis of patients with AL amyloidosis, as described in the Mayo 2004 and 2012 
staging systems[17-19]. The presence of zero, one, or two biomarkers above designated cutoff 
threshold defines stage I, II and III disease. Stage I, II and III are associated with median survival of 
26.4, 10.5 and 3.5 months respectively [20]. The threshold values have been refined over the years 
and further modifications of the system have been to incorporate serum free light chain 
concentration and  other clinical variables [21]  [20, 22-24].  Patients with stage III disease with NT-
proBNP above 8,500 pg/mL combined with a systolic blood pressure of <100 mmHg were found to 
have the poorest survival. Some reports have included high-sensitivity troponin T and I into 
prognostic models [24] [23]. The biggest limitation of this staging is the renal failure. For this 
reason is useful to consider a higher NT-proBNP cutoff when the estimated glomerular filtration 
rate (eGFR) is <60 mL/min/ 1.73 m2 but for lower values (eGFR ≥ 15 ) the corresponding BNP cutoff 
should be preferred.[25] 
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Recently CMR derived measurements of cardiac amyloid burden have been explored as new 
variables adding additional independent prognostic power over the Mayo staging systems 
[11][26].  
4. Treatment of AL amyloidosis 
4.1 Goals of therapy   
The mechanisms by which amyloid formation causes organ dysfunction are not completely 
understood, particularly in AL type. Physical and mechanical replacement of parenchymal tissue by 
amyloid deposits does not seem to fully explain the pathophysiology of AL amyloidosis, and a toxic 
effect, related to either a rapid rate of amyloid deposition or an inherent toxicity mediated  
directly by pre-fibrillary light chain protein aggregates, is thought to play an important role in the 
early mortality of patients with AL amyloidosis and cardiac infiltration.  However debate continues 
on the nature of light chain toxicity, since this is not present in the absence of substantial amyloid 
deposits.  Eradication in the shortest possible time of production of the AL amyloid fibril precursor 
protein (i.e. a haematological response measured in terms of reducing production of the aberrant 
clonal free light chains), minimization of treatment related toxicity and preservation of organ 
function are the primary goals of treatment[27, 28]. 
Achieving a haematological response translates into improved overall survival. Table 2 reports the 
consensus criteria for defining haematological and amyloidotic organ responses [28]. Although 
partial responses can be associated with some benefit, substantial 90-100% reduction in free light 
chain concentration is associated with the best clinical outcomes. According to consensus criteria 
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for hematologic response assessment [29] a very good partial response (VGPR) is defined as dFLC  
less than 40mg/L and is associated with an overall survival (OS) of 80-90% at 3 years [29]. A VGPR 
is currently considered the minimum goal of therapy.  
Serial biomarkers are extremely important in evaluating a cardiac organ response. A reduction in 
NT-proBNP of 30% and 300 ng/L from baseline following completion of chemotherapy defines a 
cardiac response [27] [59]. In patients with cardiac amyloid infiltration, the lack of such a decrease 
in NT-proBNP among those who have not achieved a complete response (CR) supports 
consideration of further therapy to obtain a deeper hematologic response. Cardiac biomarkers are 
more sensitive than echocardiographic parameters of systo-diastolic function, but worsening renal 
failure or treatment with immunomodulatory drugs confound interpretation of these biomarkers, 
highlighting a need for other methods to specifically track the amyloid deposits.[30]  
 
4.2 Supportive Care 
Supportive treatment is a fundamental part of integrated clinical management. The aim is to 
maintain a good quality of life and palliate organ function. Supportive therapy for treatment of 
heart failure due to cardiac AL amyloidosis consists primarily of diuretics with fluid restriction and 
frequent adjustment according to daily weight measurements. Management of heart failure 
symptoms in cardiac AL can be very challenging since nephrotic syndrome, renal failure, and 
autonomic dysfunction often coexist. Frequent clinical assessment as well as measurement of 
electrolytes and creatinine are mandatory. A combination of loop diuretics and aldosterone 
antagonists are the mainstay of therapy, and caution is required regarding the use of other 
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standard heart failure medications. This requires the involvement of specialists familiar with the 
disease. Digoxin and calcium channel blockers have been associated with toxicity. Angiotensin 
converting enzyme inhibitors can precipitate hypotension in AL amyloidosis and the use of beta-
blockers can cause or significantly exacerbate bradycardia, which has been shown to be a frequent 
terminal event in patients with cardiac AL amyloidosis. The alpha agonist midodrine can increase 
blood pressure in patients with orthostatic hypotension due to autonomic neuropathy. 
Gastrointestinal symptoms can sometimes be due to bacterial overgrowth and respond to 
antimicrobial therapy, whilst metoclopramide, opioids or octreotide may relieve gastroparesis and 
diarrhea respectively. Sudden cardiac death is common in patients with cardiac AL amyloidosis. 
Although implantable cardiac defibrillators can successfully terminate arrhythmias, evidence 
demonstrating their efficacy overall in prolonging survival remains lacking.[31] 
Organ transplantation may be considered in patients with end stage amyloid related organ failure 
who would subsequently be eligible for autologous stem cell transplant (ASCT) or have achieved a 
complete clonal response to prior chemotherapy. The chief concerns surrounding organ 
transplantation are the systemic nature of the disease and the likelihood of recurrent amyloid 
deposition in the graft. The increasing availability of effective chemotherapy regimens has 
increased the proportion of patients in whom renal or occasionally cardiac transplantation can be 
considered.[32, 33] 
4.3 Autologous Stem Cell Transplantation 
 
Following recognition that AL amyloidosis is caused by a clonal plasma cell disorder, treatments 
used for multiple myeloma have been applied and tested in AL amyloidosis. A significant advance 
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in myeloma treatment was autologous stem cell transplantation with high dose melphalan [34, 35] 
and this approach was adapted to patients with AL amyloidosis. The key differences between 
myeloma and amyloidosis patients soon became evident: AL patients have a lower tumor burden, 
but are significantly more fragile and often have multiple organ dysfunction.  The mortality of the 
procedure in AL amyloidosis varies greatly with patient selection, but there is an overall 15% 
incidence of major complications during stem cell mobilization and collection, and a mortality rate 
of around 2-10%[37].  Appropriate patient selection is the key to reduction in morbidity and 
mortality and clinically significant cardiac amyloidosis is a contraindication. 
Patients with AL amyloidosis can be in different categories of risks: low, intermediate, or high risk. 
Low risk patients (<20% of all cases) are potential candidates for ASCT[22, 38, 39]. Although a 
small randomised trial did not prove superiority of ASCT over standard chemotherapy[40], data 
from various non-randomised studies show excellent hematological response rates and long term 
surivival. In one large center, 56% of patients achieved a VGPR [41], 44% of whom achieved a CR 
[42] that translated into improvement in organ function in three-quarters of cases, progression 
free survival longer than 8 years and median overall survival greater than 10 years[43]. ASCT can 
be performed relatively safely with strict patient selection, particularly using cardiac biomarkers 
with recent treatment-related mortality lower than 10%[38]. A strategy in which bortezomib is 
used for induction or consolidation seems to achieve the desired VGPR target in >90% of treated 
patients[44, 45]. ASCT is best undertaken in centers with particular experience in amyloidosis with 
the procedure. 
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4.4 Combination Chemotherapy  
 
Most patients with AL amyloidosis can be classified to be of intermediate risk and are treated with 
less intensive combination chemotherapy regimens. Choice of treatment has grown substantially 
of late with development of many novel agents for myeloma, and few comparative clinical trials in 
amyloidosis have been performed.  Recommendations for treatment and guidelines documents 
remains very much based on consensus of expert clinicians. 
Alkylators and steroid based regimens. The first effective chemotherapy protocol for multiple 
myeloma was oral melphalan and prednisone, and a randomized clinical trial showed that this 
regimen had a small survival benefit for patients with AL amyloidosis. For more than 40 years 
alkylating agents and, more specifically, melphalan and corticosteroids have been considered the 
mainstay in treatment of AL amyloidosis [46]. The melphalan-dexamethasone (MDex) regimen is 
well tolerated with just 10-15% experiencing severe adverse events, mainly comprising fluid 
retention and cytopenias, and is associated with good haematological (67%) and organ (33%) 
response rates, with a third of patients achieving a complete clonal response. However the rates 
of hematological response to melphalan and prednisolone were relatively low and delayed 
allowing organ dysfunction to progress [27, 46]. MDex treatment remains an option for non-
transplant eligible patients due to its low toxicity, simple oral formulation and eventual ability to 
produce good hematological responses even in patients with multiple organ involvement [47]. The 
role of MDex in patients with advanced cardiac disease is uncertain [48], since there is a strong 
rationale to obtain a more rapid response. 
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Multidrug regimens containing doxorubicin, vincristine and dexamethasone [49] or vincristine with 
multiple alkylator agents [50] were tested but did not show superiority over melphalan and 
dexamethasone. Pulsed dexamethasone has also been shown to be active in AL amyloidosis but 
high doses of dexamethasone cause considerable toxicity most commonly in patients with 
nephrotic syndrome and heart failure. 
Bendamustine is an alkylator with a novel mechanism of action that has been used with steroids in 
relapsed/refractory disease [51]. Bendamustine needs to be explored earlier in the course of the 
disease.  
Immunomodulatory Agents. The first generation agent thalidomide was poorly tolerated as a 
monotherapy and was associated with significant toxicity [52]. The combination of thalidomide 
and dexamethasone was more effective with overall clonal response rates of 48%. The median 
time to response was 3.6 months[53] but this was associated with significant toxicity. Dose 
adapted CTD (cyclophosphamide + thalidomide-dexamethasone), a risk adapted strategy based on 
patients clinical status, has been used with good and rapid hematologic responses[54] but 
relatively high toxicities[55]. This regime evolved as the standard of care in the UK before 
bortezomib was introduced in recent years.  
Lenalidomide is an analogue of thalidomide with a superior toxicity profile in myeloma, and is now 
widely used in combination with dexamethasone (Len/dex) as a treatment for AL amyloidosis. Two 
phase II studies showed good haematological responses in 67% (n=24), with CR and partial 
response (PR) in 29% and 38% respectively.[56, 57]. Lenalidomide doses were often reduced 
because of myelosuppression. A Len/dex protocol has been tested in a small cohort of patients 
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refractory to thalidomide, bortezomib and alkylators, supporting their role in salvage treatment 
[58]. 
Complete response rates remain low with lenalidomide based regimes and addition of an alkylator 
have been tested in an attempt to improve the response rate [30, 59-62], but this incurred 
significant toxicity [27]. The most common adverse effects were myelosuppression and 
thromboembolism (hematologic side effects), fatigue and skin rush (non-hematologic side 
effects)[3][59].  
A third generation Immunomodulatory imide drugs (IMiDs), pomalidomide, first used in myeloma 
patients refractory to lenalidomide, has been used in combination with dexamethasone [63] in 
refractory patients, showing promise for the use as salvage therapy. 
IMiD’s, although effective and an important part of the treatment in AL amyloidosis, are poorly 
tolerated compared with their use in multiple myeloma. During treatment with these agents an 
increase in cardiac biomarkers has been described [64] but this has not been associated with poor 
survival or renal deterioration.[30]  
 
Proteasome inhibitor based regimens. Bortezomib, a reversible proteasome inhibitor, was 
developed with the aim of suppressing proliferation of proliferative malignant B-cell populations 
by inducing apoptosis [65]. Inhibition of proteasome function in plasma cells triggers apoptosis 
thought stress-activated protein kinases and mitochondrial signaling pathways. Amyloidogenic 
plasma cells that produce misfolded light chains overloads the ubiquitin proteasome system and 
may be therefore more vulnerable to proteasome inhibitors. Clinical and Phase II clinical trial 
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experience have led to bortezomib combinations emerging as front line standard of care therapy 
in AL amyloidosis. 
In the first study of bortezomib and dexamethasone on 18 patients, five had hematologic and 
organ progression with an average of 6.8 survival months [66]. A study conducted by National 
Amyloidosis Centre (UK) on 20 patients treated with bortezomib alone, revealed 80% 
haematological response rates and 30% organ responses. Data from multicentre retrospective 
analysis on 94 patients treated with bortezomib with or without dexamethasone showed high 
hematologic response rates (71%) that were achieved rapidly and were associated with 
consequent organ responses in 30% and one year survival of 76% [65]. A prospective phase I/II 
trial reported similar efficacy in patients with relapsed refractory AL amyloidosis which were 
divided in two groups based on once or twice weekly dosing [67].  
A combination of bortezomib with cyclophosphamide and dexamethasone (CyBorD) is associated 
with very high response rates exceeding 90% for patients treated upfront, with 60% achieving CR 
or VGPR[68, 69]. This treatment therefore offers the hope of rapid and deep clonal responses and 
improvements in organ function, including the heart. However a recent study, on 230 patients 
treated frontline with CyBorD, showed 60% of hematologic response rate (43% VGPR), with 
cardiac and renal response reached in just in 17% and 25% respectively [70]. An ongoing 
randomised prospective trial is comparing MDex with bortezomib-melphalan-dexamethasone 
(BMDex). Novel proteasome inhibitors ixazomib and carfilzomib have higher specific activity than 
bortezomib that may be relevant clinically, and a different and potentially more favourable toxicity 
profile. A phase I study of oral ixazomib has been completed with good haematological response 
and tolerance and responses also in refractory patients [71]. A phase III trial is currently ongoing.  
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4.5 IgM associated AL amyloidosis 
Six to seven percent of all patients with AL amyloidosis have an IgM secreting lymphoplasmacytic 
lymphoma as their underlying clonal hematologic disease [72, 73]. AL amyloidosis caused by IgM 
clones is a specific and distinct clinical entity characterized by more frequent involvement of the 
peripheral nervous system and limp nodes and less cardiac involvement[74].  Combining NT-
proBNP, Troponin T with liver involvement and presence of neuropathy gives in this population a 
better risk model [74].  Chemotherapy treatment should be directed toward the IgM clone. Single 
agent alkylators have shown limited efficacy. Regimes such as melphalan/dexamethasone and 
purine analogues are associated with good hematologic responses [72, 73]. Data for 250 patients 
with IgM related AL amyloidosis were recently published from a European multicentre study. Fifty-
seven percent of patients achieved a hematological response (14% VGPR/CR) with median overall 
survival not reached for patients achieving VGPR/CR, 64 months for PR, and 28 months for 
nonresponders[20]. The data from this study confirmed that deeper hematological response 
translated into better outcomes, but deep hematological responses remain infrequent with 
currently available treatment.  
5. An approach to treatment  
Early diagnosis remains the holy grail in patients with AL amyloidosis since it allows the broadest 
range of therapeutic options at a stage where amyloidotic organ function has the best chance of 
being preserved. The treatment strategy is tailored patient by patient, and the choice is guided by 
factors including age, co-morbidities, performance status, organ involvement/dysfunction and 
relevant drug toxicities. Due to lack of clear evidence from randomized trials, patient preferences 
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must also be taken into account. The algorithm of Figure 4 presents the standard of care at our 
centre for patients treated outside clinical trials.  
The choice of upfront treatment is between autologous stem cell transplantation (ASCT) and 
combination chemotherapy. Cardiac biomarkers have a central role in the selection of patients for 
ASCT. Younger patients with  cTnT<0.06 ng/mL, NT-proBNP<5000 ng/L, good performance status, 
limited organ involvement and good renal function have  <5% transplant-related mortality  during 
ASCT[22, 75, 76]. This group of patients should be offered ASCT as a treatment choice. Patients 
with a bone marrow cell infiltrate >10% have a poor outcome [77]and benefit from induction 
treatment before ASCT [78].  Recently fluorescent in situ hybridization (FISH) abnormalities have 
been associated with different treatment outcomes, suggesting possible new approaches to guide 
treatment strategies [79, 80]. Borderline patients should be treated with a stem cell sparing 
regime as improved organ function may allow ASCT at a later date. In non neuropathic patients 
CyBorD or BMDex are becoming the regimens of choice.  Treatment is best delivered in hospital 
with cardiac monitoring in patients with advanced cardiac involvement. Patients with neuropathy 
or those who develop it as an adverse effect of bortezomib can be offered 
melphalan/dexamethasone or lenalidomide/dexamethasone. Response reassessment after 3 
cycles of treatment is key – patients with a poor response should be considered for either dose 
increments, additional agents eg thalidomide, or switching to an alternative regimen to improve 
response.  
Amyloidotic organ responses occur most often among patients achieving a hematologic CR/VGPR, 
but a proportion of partial responders can also achieve an organ response, emphasizing the need 
to closely track the latter as well as the hematologic disorder . Lenalidomide and pomalidomide 
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based regimens or Bendamustine are useful in relapsed patients or in patients that are refractory 
to other treatments. The utility of alkylator-based regimes in patients relapsing after a novel agent 
is currently unclear.   
No regimen has yet been proven to be superior or to reduce early cardiac deaths in patients that 
are very high-risk [20]. The rational desire for a rapid response underpins widespread adoption of 
bortezomib-based regimens, but superiority to other regimens has not been proven yet[81]. 
Improved outcomes in this subset are a major unmet medical need. 
6. Enhancing regression and interfering with amyloidgenesis  
An attractive challenge in recent years has been to develop therapeutic antibodies that target 
amyloid deposits and promote their clearance. Mu11-1F4 is a chimeric antibody that binds to 
many AL fibrils [82] and is now in phase 1 clinical trial. A phase I/II study has been recently 
completed in patients with AL amyloidosis with another monoclonal antibody, NEOD001 (Onclave 
Therapeutics Limited, California), reporting good safety and tolerability and a suggestion of cardiac 
improvement; Of the 14 cardiac-evaluable patients, 8 (57%) met the criteria for cardiac responses 
and 6 (43%) has stable disease.  A  phase II expansion is ongoing and a global phase III randomized 
trial has lately been initiated[83]).  
Serum amyloid P component (SAP) binds to all amyloid fibrils and there is  in vitro evidence that 
SAP  protects them from degradation by phagocytic cells and proteolytic enzymes. The (R)-1-[6-
[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid (CPHPC) efficiently  
depletes SAP from the blood [84] but leaves some SAP in the amyloid deposits. SAP in the amyloid 
deposits can then be specifically targeted by therapeutic humanized monoclonal anti-SAP 
antibodies. A phase I trial involving 15 patients with amyloidosis has confirmed that this approach 
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can safely trigger clearance of amyloid deposits from the liver and some other sites including the 
kidney [85]. No serious adverse events were observed. A phase II study to investigate patients 
with cardiac amyloidosis is in planning.   
The epigallocatechin gallate, a naturally derived phenol which is particularly present in the green 
tea, is able to interfere with the aggregation of the amyloidogenic proteins in vitro[86]. A case-
control study of 11 patients treated with MDex associated with the consume of green tea, showed 
decreasing of symptoms and cardiac mass when compared to 22 historical controls[87]. The 
results are more promising for TTR cardiac amyloidosis[88], but his use on AL amyloidosis is now in 
phase 1 clinical trial [89].Furthermore there are new evidences that show how Epigallocatechin 
gallate antagonize bortezomib action in vitro [90]. 
Doxycycline, an antibiotic with similar structure to anthracycline 4'-iodo-4'-deoxy- 
doxorubicin (able to inhibit amyloidogenesis in vitro)[91, 92], has been shown to disrupt amyloid 
in a transgenic mice model and is able to counteract the proteotoxicity of amyloidogenic light 
chains. [93]Finally in a small retrospective case control study the addition of of doxycycline to 
chemotherapy  improved survival of patients with stage II/IIIa. However patients in this study were 
matched based on the severity of the dis ease but not for chemotherapy regimen received.[94] 
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7. Conclusions 
Treatment of systemic AL amyloidosis has changed markedly in the last 10 years, as novel 
chemotherapy agents have become available.  This has translated into improved overall survival, 
but challenges remain in advanced disease where the median survival is still very poor. FLC and 
blood biomarkers (troponin and brain natriuretic peptides) guide the selection and duration of 
treatment strategies. Treatments will continue to change, but the key target remains early 
diagnosis before end-stage organ failure has occurred. Broadening the amyloid-specific 
therapeutic landscape with immunotherapeutic targeting of amyloid deposits holds promise to 
transform outcomes in systemic AL amyloidosis. 
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8. Expert opinion 
AL amyloidosis is the most common type of systemic amyloidosis, but is rare overall and remains 
challenging to diagnose. The presenting clinical picture is variable and depends substantially on 
which organs are involved. Symptoms are often very non-specific.  New diagnostic techniques 
have enabled earlier detection of disease and much improved characterization of organ 
involvement, but many patients continue to be diagnosed at a late stage when the function of one 
or more organs has become significantly impaired. The diagnosis requires confirmation of the 
presence of AL amyloid deposits, along with characterization of the underlying clonal 
hematological disorder.  
Suppression of the AL amyloid light chain precursor protein (i.e. a haematological response) in the 
shortest possible time, minimization of treatment related toxicity and preservation of organ 
function are the primary goals of treatment. Baseline assessment of amyloid related organ 
dysfunction is required to stratify prognosis and tailor the most appropriate treatment for each 
patient.  The presence and severity of cardiac involvement are the main determinants of outcome 
in patients with AL amyloidosis. Risk stratification using the serum cardiac biomarkers troponin 
and brain natriuretic peptides has refined treatment choices and has led to reduced morbidity and 
mortality, but selection of the optimal treatment for each patient remains complex and requires a 
multidisciplinary approach.   
Few patients are too sick to embark on chemotherapy and choice of first line treatment lies 
between ASCT and combination chemotherapy. ASCT is associated with excellent and durable 
clonal responses in about half of patients and probably the best outcomes in terms overall 
survival, but meticulous patient selection, mainly based on the use of blood biomarkers, is key to 
  
 
 
 
 
 
 
 
 
 
 
 
 
22 
 
 
minimizing morbidity and mortality, and significant cardiac amyloidosis is an important 
contraindication.   AL amyloidosis patients can be classified at diagnosis as at low, intermediate, or 
high risk. Low risk patients (<20% of all cases) are potential candidates for ASCT, whilst 
intermediate and high risk patients should be considered for combination chemotherapy. 
Borderline patients should be treated with a stem cell sparing regime, since ASCT may remain a 
treatment option later on.  In intermediate and low risk patients, novel agent based 
chemotherapy, especially including bortezomib, has greatly improved the speed and depth of 
hematologic responses and is being explored as an adjunct before and after ASCT. Bendamustine, 
lenalidomide and pomalidomide are valuable therapies for patients whose clonal disease has 
relapsed or is refractory.  
Early mortality among patients with advanced disease remains a major challenge, and nearly 25% 
of all patients still die of complications within a few months of diagnosis. Patients achieving a 
hematologic CR/VGPR have the best chance to achieve organ responses, but stabilization or 
improvement in amyloidotic organ function does occur in a proportion of patients with only partial 
hematologic responses, emphasizing the need to track organ function closely in all cases as a guide 
to the need for ongoing therapy. Frequent assessments of haematological response are required: 
our practice is to conduct a broad review after 3 cycles of treatment, and patients with a poor 
response are considered for dose increments, additional agents or alternative regimens.  
Future directions include therapies that directly target amyloid deposits or inhibit fibrillogenesis. 
These molecules are now well advanced in development and have the potential to reshape the 
treatment of AL amyloidosis when used in conjunction with the many new chemotherapy agents 
that are already finding their place in clinical practice.  
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Table 1: Most common types of systemic amyloidosis. 
TYPE Abbreviation 
Precursor 
and pathogenesis 
Site of 
Synthesis 
Organs Involved 
 
Immunoglobulin 
Light Chain 
Amyloidosis 
AL 
 
Monoclonal 
Light chain 
(primary) 
Bone 
marrow 
or serum B 
cell clone 
Heart, kidneys, GI tract, 
liver, autonomic and 
peripheral nerves, soft 
tissue 
Systemic AA 
(reactive systemic 
amyloidosis) 
AA 
Serum amyloid A 
protein 
(increased 
production in 
chronic 
inflammation) 
Liver 
Kidneys, GI tract, 
spleen, liver, autonomic 
nerves 
Hereditary 
transthyretin 
Amyloidosis 
ATTRm 
(hereditary 
mutation) 
 
 
More than 100 
mutation known 
(hereditary) 
 
Liver 
Peripheral and 
autonomic nerves, 
heart, leptomeninges, 
eye 
Wild type 
transthyretin 
Amyloidosis 
 (ATTRwt) 
Wild type 
Transthyretin 
 
 
Liver Heart 
Fibrinogen Amyloidosis AFib 
Fibrinogen 
A α-chain 
(hereditary) 
 
Liver Kidneys 
Apolipoprotein A1 AApoA1 
Apolipoprotein 
A1 
(hereditary) 
 
Liver, 
intestine 
Heart, liver, kidneys, 
skin, larynx 
Leukocyte chemotactic 
factor 2 
ALECT2 
Leukocyte 
chemotactic factor 2 
 
Liver 
Kidneys, liver, spleen, 
lung 
 
GI tract, gastro-intestinal tract. 
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Table 2: Consensus Hematologic and Organs Response in AL amyloidosis [27] 
 
 
 
 
 
 
 
 
 
 
 
 
 
dFLC – difference between involved and uninvolved free light chains. 
 
 
 
 
 
 
 
RESPONSE TYPE CRITERIA 
Hematological 
response 
Complete 
response(CR) 
Negative serum and urine immunofixation 
and normal κ/λ ratio  
Very good partial 
response (VGPR) 
dFLC < 40mg/L 
Partial response 
(PR) 
dFLC  reduction ≥ 50% 
No response (NR) A less than 50% response in dFLC 
Organ 
response 
Heart 
NT-proBNP response (>30% and >300 ng/l 
decrease in patients with baseline NT-proBNP 
≥650 ng/l) or NYHA class response (≥2 class 
decrease in subjects with baseline NYHA class 
3 or 4) 
Kidney 
50% decreased urinary protein excretion in 
24-hour without a reduction in eGFR ≥ 25% or 
an increase in serum creatinine ≥0.5 mg/dL  
Liver 
50% decreased alkaline phosphatase value. 
Liver size decrease >2 cm  
Peripheral nervous 
system 
Improvement in electromyogram nerve 
conduction velocity 
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Figure 1: The algorithm of standard of care for patients treated outside clinical trials 
 
 
 
 
 
 
 
 
Refer to a specialist center 
for: 
 Assessment of distribution 
 Typing for non- AL 
Amyloidosis 
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Figure 2: Typical diagnostic amyloid findings on histological examination: Congo red staining (A), 
apple-green birefringence under cross-polarized light (B). Immunostaining with antibodies to 
kappa light chains (negative) (C) and with antibodies to lambda (positive) (D)  
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Figure 3: Main diagnostic techniques for cardiac AL amyloidosis. ECG, showing low voltages in the 
limb leads (A); echocardiography, showing concentric left ventricular hypertrophy and biatrial 
dilatation (B); late gadolinium enhancement image by cardiac magnetic resonance  showing the 
typical subendocardial late gadolinium enhancement coupled with abnormal blood pool 
gadolinium kinetics (C); non contrast T1 map by cardiac magnetic resonance  showing elevated 
native myocardial T1 (D). 
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Figure 4. Treatment algorithm in systemic AL amyloidosis patients. 
 
ASCT, autologous stem cell transplantation; NT-proBNP, amino-terminal pronatriuretic 
peptide type-B; NYHA, New York Heart Association; SBP, systolic blood pressure.; MDex, 
melphalan /dexamethasone; BDex, bortezomib dexamethasone; CyBorD, cyclophosphamide / 
bortezomib /dexamethasone; BMDex, bortezomib / melphalan / dexamethasone. 
 
 
 
 
Sistemic	AL	amyloidosis
ASCT	eligible ASCT	non	eligible
Low	risk	patient:	
• NT-proBNP	<5000	pg/ml	
• TroponinT	<0.06	ng/ml	
• NYHA	class	<	III	
• Good	renal	function	
• SBP	(standing)	>	90	mm	Hg
Intermediate	risk	patient:	
Mayo	stages	I-IIIa
High	risk	patient:	
Mayo	Stage	IIIb	
NYHA	class	≥III
1. Dose	adapted	melphalan	
conditioned	ASCT
1. MDex		
2. CyBorD	
3. BMDex
Combination	chemotheraphy		
in	low	dose
Relapsed	or	refractory	disease
• Proteasome	inhibitor	based	regimens	
• Alkylators	and	steroid	based	regimens.	
• Immunomodulatory	Agents
2. Combination	
chemotheraphy	
Choice	of	
the	patient
